Novartis buoyed by trial success in early-stage breast cancer Ruchika Sharma29 March 2023 9:15 AM ISTFrankfurt: Novartis's Kisqali breast cancer drug cut the risk of recurrence in women who were diagnosed at an early stage of the disease in a pivotal...
Novartis halts UK trial of anticholesterol drug Leqvio Dr. Nandita Mohan23 March 2023 6:00 PM ISTNovartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally planned as part of...
Health Bulletin 23/March/2023 Dr. Nandita Mohan23 March 2023 4:25 PM ISTHere are the top health stories for the day:New Bond Policy: Gujarat proposes 1.5 years of mandatory service for doctors completing MBBS, PG...
Novartis not to move ahead with UK trial of anti-cholesterol drug Leqvio Ruchika Sharma22 March 2023 4:00 PM ISTBerlin: Novartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally...
Novartis secures USFDA nod for Tafinlar plus Mekinist for pediatric brain cancer Ruchika Sharma17 March 2023 2:35 PM ISTLow grade glioma is the most common pediatric brain cancer.
Novartis launches new USD 11 billion share buyback Ruchika Sharma13 March 2023 10:00 AM ISTZurich: Novartis has formally launched its new share buyback programme where it could spend up to 10 billion Swiss francs ($10.90 billion)...
Novartis, Teijin Pharma ink pact for preclinical candidate for proteinuric kidney diseases Ruchika Sharma8 March 2023 3:30 PM ISTTeijin Pharma will receive an upfront cash payment of USD 30 million from Novartis and is eligible to receive potential development and commercial...
Novartis names Gilbert Ghostine as Chairman designate of Sandoz Board of Directors Ruchika Sharma20 Feb 2023 3:30 PM ISTGhostine is an experienced business leader with a track record of growing and transforming businesses in competitive industries.
Operating profit to grow again ahead of Sandoz spin off: Novartis Ruchika Sharma1 Feb 2023 10:00 AM ISTNovartis said in its statement it's on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its...
Novartis gets European Commission nod for Pluvicto to treat progressive PSMA-positive metastatic castration-resistant prostate cancer Ruchika Sharma17 Jan 2023 3:30 PM ISTPluvicto is an intravenous radioligand therapy combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in...
EMA seeks to issue guidance on liver damage from Novartis gene therapy Zolgensma Ruchika Sharma15 Jan 2023 12:15 PM ISTThe drug won conditional EU approval during early 2020 and it costs more than $2 million per patient
Novartis gets CDSCO Panel nod to market anticancer drug Trametinib and Dabrafenib for additional indication Dr. Divya Colin1 Jan 2023 5:45 PM ISTNew Delhi: In a significant development, the drug major Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the...
